131 related articles for article (PubMed ID: 37271526)
21. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
DeZern AE; Greenberg PL
Blood; 2023 Dec; 142(26):2258-2267. PubMed ID: 37562001
[TBL] [Abstract][Full Text] [Related]
22. A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes.
Wang YH; Hou HA; Lin CC; Kuo YY; Yao CY; Hsu CL; Tseng MH; Tsai CH; Peng YL; Kao CJ; Chou WC; Tien HF
Blood Adv; 2021 Nov; 5(22):4535-4548. PubMed ID: 34614508
[TBL] [Abstract][Full Text] [Related]
23. New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.
Tothova Z; Steensma DP; Ebert BL
Clin Cancer Res; 2013 Apr; 19(7):1637-43. PubMed ID: 23329810
[TBL] [Abstract][Full Text] [Related]
24. [Myelodysplastic syndrome : prognostic factors].
Gyan E; Thépot S
Bull Cancer; 2023 Nov; 110(11):1141-1146. PubMed ID: 37537115
[TBL] [Abstract][Full Text] [Related]
25. Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
Mangaonkar AA; Swoboda DM; Lasho TL; Finke C; Ketterling RP; Reichard KK; Komrokji R; Padron E; Patnaik MM
Leuk Res; 2023 Aug; 131():107340. PubMed ID: 37356165
[No Abstract] [Full Text] [Related]
26. How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.
Xian RR
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):51-58. PubMed ID: 38066895
[TBL] [Abstract][Full Text] [Related]
27. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
Sabile JMG; Kaempf A; Tomic K; Manu GP; Swords R; Migdady Y
Leuk Lymphoma; 2023 Oct; 64(10):1689-1694. PubMed ID: 37440338
[TBL] [Abstract][Full Text] [Related]
28. Impact of the International Consensus Classification of myelodysplastic syndromes.
Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment.
Nachtkamp K; Kobbe G; Gattermann N; Germing U
Dtsch Arztebl Int; 2023 Mar; 120(12):203-210. PubMed ID: 36718105
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
Curr Hematol Malig Rep; 2024 Jun; 19(3):138-150. PubMed ID: 38632155
[TBL] [Abstract][Full Text] [Related]
31. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes.
Mosquera Orgueira A; Perez Encinas MM; Diaz Varela NA; Mora E; Díaz-Beyá M; Montoro MJ; Pomares H; Ramos F; Tormo M; Jerez A; Nomdedeu JF; De Miguel Sanchez C; Leonor A; Cárcel P; Cedena Romero MT; Xicoy B; Rivero E; Del Orbe Barreto RA; Diez-Campelo M; Benlloch LE; Crucitti D; Valcárcel D
Hemasphere; 2023 Oct; 7(10):e961. PubMed ID: 37841754
[TBL] [Abstract][Full Text] [Related]
32. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Zhao L; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakiuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori-Kondo A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemanuil E; Miyazaki Y; Hellström-Lindberg E; Ogawa S
Blood Adv; 2023 Jul; 7(14):3624-3636. PubMed ID: 36989067
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome.
Ma J; Gu Y; Wei Y; Wang X; Wang P; Song C; Ge Z
Blood Sci; 2023 Jul; 5(3):187-195. PubMed ID: 37546714
[TBL] [Abstract][Full Text] [Related]
34. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
[TBL] [Abstract][Full Text] [Related]
35. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M; Bewersdorf JP; Xie Z; Porta MGD; Komrokji R; Xu ML; Abdel-Wahab O; Taylor J; Steensma DP; Starczynowski DT; Sekeres MA; Sanz G; Sallman DA; Roboz GJ; Platzbecker U; Patnaik MM; Padron E; Odenike O; Nimer SD; Nazha A; Majeti R; Loghavi S; Little RF; List AF; Kim TK; Hourigan CS; Hasserjian RP; Halene S; Griffiths EA; Gore SD; Greenberg P; Figueroa ME; Fenaux P; Efficace F; DeZern AE; Daver NG; Churpek JE; Carraway HE; Buckstein R; Brunner AM; Boultwood J; Borate U; Bejar R; Bennett JM; Wei AH; Santini V; Savona MR; Zeidan AM
Blood Rev; 2023 Nov; 62():101128. PubMed ID: 37704469
[TBL] [Abstract][Full Text] [Related]
36. Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes.
Yao CY; Lin CC; Wang YH; Kao CJ; Tsai CH; Hou HA; Tien HF; Hsu CL; Chou WC
Blood Adv; 2024 May; 8(10):2442-2454. PubMed ID: 38527292
[TBL] [Abstract][Full Text] [Related]
37. Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes.
Mendoza H; Siddon AJ
Clin Lab Med; 2023 Dec; 43(4):549-563. PubMed ID: 37865502
[TBL] [Abstract][Full Text] [Related]
38. Molecular patterns identify distinct subclasses of myeloid neoplasia.
Kewan T; Durmaz A; Bahaj W; Gurnari C; Terkawi L; Awada H; Ogbue OD; Ahmed R; Pagliuca S; Awada H; Kubota Y; Mori M; Ponvilawan B; Al-Share B; Patel BJ; Carraway HE; Scott J; Balasubramanian SK; Bat T; Madanat Y; Sekeres MA; Haferlach T; Visconte V; Maciejewski JP
Nat Commun; 2023 May; 14(1):3136. PubMed ID: 37253784
[TBL] [Abstract][Full Text] [Related]
39. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.
Schulz E; Aplan PD; Freeman SD; Pavletic SZ
Blood Adv; 2023 Aug; 7(16):4381-4394. PubMed ID: 37267435
[TBL] [Abstract][Full Text] [Related]
40. There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.
Zeidan AM; Komrokji RS
Curr Hematol Malig Rep; 2013 Dec; 8(4):351-60. PubMed ID: 23979829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
